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Abstract
Purpose of Review The lack of clarity about the effect of
cannabis use on cognition may be attributable to the consid-
erable heterogeneity among studies in terms of cannabis com-
position. This article selectively reviews studies examining
the distinctive effects of cannabinoids on human cognition,
particularly those of delta-9-tetrahydrocannabinol (Δ9-THC)
and cannabidiol (CBD).
Recent Findings Research indicates that Δ9-THC administra-
tion acutely impairs cognition, particularly memory and emo-
tional processing. Limited evidence suggests that CBD ad-
ministration might improve cognition in cannabis users but
not in individuals with neuropsychiatric disorders.
Moreover, studies indicate that some acute Δ9-THC-induced
cognitive impairments may be prevented if Δ9-THC is ad-
ministered in combination or following CBD treatment. Δ9-
THC and CBD have also shown opposite effects on cognition-
related brain activation, possibly reflecting their antagonistic
behavioral effects.
Summary Research suggests greater cognitive impairments in
individuals when exposed to high Δ9-THC or low CBD can-
nabis. It is unclear whether at specific concentrations CBD
might outweigh any harmful effects ofΔ9-THC on cognition.
Keywords Cannabis . Delta-9-tetrahydrocannabinol .
Cannabidiol . Cognitive processing . Brain function
Introduction
Interest in the effects of cannabis on human cognition stems
from evidence regarding its role as the most widely used illicit
drug [1] as well as an important risk factor for the develop-
ment of psychosis [2, 3] and its relapse [4–8], the latter being
a l s o c o n s i s t e n t w i t h e v i d e n c e t h a t d e l t a - 9 -
tetrahydrocannabinol (Δ9-THC), the main psychoactive in-
gredient of the Cannabis sativa plant, can induce transient
psychotic symptoms upon acute administration in healthy vol-
unteers [9–11]. This body of research is also consistent with
independent evidence of endocannabinoid system abnormali-
ties in psychosis [12], a disorder characterized by abnormali-
ties in different cognitive processes [13].
However, evidence regarding the association between can-
nabis use and impairments in cognitive processing is less
clear. While one may intuitively expect cannabis to have a
deleterious effect on cognitive performance, studies in healthy
volunteers have reported some discrepancies. For example,
some studies suggest that healthy cannabis users show poorer
cognitive performance [14–17]. Others report no difference in
cognitive processing as a function of cannabis use [18]. Even
more conflicting results are present in studies in patients with
schizophrenia. While some studies suggest poorer cognitive
functions in patients with a history of cannabis exposure [19],
others indicate better performance [15, 20] or no change [17,
21] in cannabis-using patients.
Variation in the results of studies investigating the effect of
cannabis use on cognitive functioning, as outlined above,
might have several explanations. These discrepancies may
be because of genetic variation having an impact on cognitive
phenotypes [22–29]. Moreover, it may reflect selective effect
on certain aspects of cognition as suggested by available evi-
dence, with a robust but modest deleterious impact on global
memory function, a more pronounced detrimental effect on
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specific memory sub-domains such as prospective and retro-
spective verbal and visual memory, and limited effect on other
cognitive domains [17, 30]. It may also reflect variation be-
tween different studies in the duration of cannabis exposure
and/or of abstinence at the time of cognitive testing of study
participants, as available evidence points towards a dose-
dependent effect with cognitive impairment being more
marked following persistent cannabis use and incomplete res-
toration of function following cessation of use [31]. Evidence
from imaging studies also suggests that both chronic [32, 33]
and acute cannabis exposure [34] might disrupt activity in
brain networks involved in cognitive processing without nec-
essarily affecting behavioral performance, suggesting either a
deployment of greater neural effort or a change in strategy to
maintain adequate task performance [35], thereby accounting
for different effects in different individuals.
Independent of these potential explanations, the lack of
a clear association between cannabis use and impairments
in cognition may also to a large extent be attributable to
the considerable heterogeneity in recreational cannabis
that participants in these studies may have been exposed
to, as well as the differing effects on cognition of the
various chemicals found in the extract of the cannabis
plant. The extract of Cannabis sativa has over 60 different
cannabinoids [36], with Δ9-THC and cannabidiol (CBD)
being the most prominent among them. However, while
Δ9-THC is thought to be responsible for most of its psy-
chotropic effects [37], CBD is under investigation for its
potential antipsychotic effects, in opposition to the pro-
psychotic effects of Δ9-THC. Research also suggests that
CBD can counteract the negative effects of Δ9-THC, as
investigated in both humans and animal models at a be-
havioral and neurochemical level [38–41]. This is of cru-
cial importance considering that case-control studies sug-
gest that the risk of development and relapse of psychosis
in cannabis users depends on both frequency of use and
cannabis potency [5, 42], with the risk being the highest
in individuals exposed on a daily basis to cannabis with a
high Δ9-THC concentration, and unchanged among users
of cannabis with a lower Δ9-THC concentration and a
more balanced Δ9-THC:CBD ratio. In line with evidence
from human studies, research investigating the effect of
different cannabinoids in animal models has consistently
reported behavioral abnormalities following Δ9-THC ex-
posure. Δ9-THC exposure during adolescence has been
associated with long-term behavioral alterations in adult
rats, such as recognition memory deficits, social with-
drawal, and altered emotional reactivity [43]. Other evi-
dence suggests enduring cognitive impairment in the off-
spring of rats exposed to Δ9-THC during the perinatal
period [44]. Interestingly, altered behavior and cognition
in animal models may be directly related to the Δ9-THC-
induced dys func t ion o f the g lu tamate rg ic and
noradrenergic systems via cannabinoid receptor 1 activa-
tion, and this altered neurotransmission can be prevented
or reversed if CBD is administered before or after Δ9-
THC exposure, respectively [40, 43, 44].
Together, these findings underscore how the effects of dif-
ferent cannabinoids, which are often present in varying con-
centration in the cannabis available for use in the street, may
confound the results of human studies investigating cognitive
alterations associated with recreational cannabis use. In this
article, we carry out a narrative review of studies examining
the acute effects of cannabis on human cognition and related
brain function, with emphasis on the distinctive effects of the
different cannabinoids that have been examined to date, par-
ticularlyΔ9-THC and CBD, in order to disentangle their con-
tribution to specific cognitive processes.
Methods
In order to disentangle the effect of different cannabinoids on
cognitive domains relevant to neuropsychiatric disorders, this
literature review aimed to mainly focus on human studies that
examined the impact of Δ9-THC in contrast with CBD and
other cannabinoids on cognitive functioning using cannabis/
cannabinoid challenge paradigms. Functional magnetic reso-
nance imaging (fMRI) studies examining the neural correlates
of the effects of Δ9-THC and CBD on human cognition and
the role of other cannabinoids in modulating cognitive pro-
cesses during a cannabis/Δ9-THC challenge are also
discussed.
Search Strategy
A literature search was performed using electronic databases
(MEDLINE, Web of Science, and Scopus) for original
English-language research articles published over the last
25 years (1990–2016). Keywords included delta-9-tetrahydro-
cannabinol, cannabidiol, cognition, cognitive dysfunction/im-
pairment, and memory/learning. Reference lists of eligible
studies were also screened to identify additional studies.
Eligibility Criteria
Studies were eligible for inclusion in this review if they had
assessed the effect ofΔ9-THC and CBD or another cannabi-
noid on cognition during acute challenge investigations.
Studies were excluded if they (i) did not assess the effects of
Δ9-THC, CBD, or other cannabinoids on cognition in exper-
imental studies; (ii) did not investigate the role of different
cannabinoids on cognition; (iii) primarily assessed psycholog-
ical or psychiatric parameters rather than cognition.
Curr Addict Rep
Results
Evidence at a Glance
A number of studies have assessed the effect of Δ9-THC
alone on cognition [41, 45–49]. However, only a limited body
of research has specifically compared the effect of different
cannabinoids on human cognition, which has also been
reviewed before focusing primarily on neuroimaging studies
[41, 49]. These studies have used different experimental de-
signs and studied heterogeneous populations. In particular,
eight human studies were identified on the behavioral effects
of Δ9-THC and CBD, which investigated (i) cognitive func-
tion in cannabis users using products with a high or low Δ9-
THC:CBD ratio, in both the intoxicated and unintoxicated
state [50, 51]; (ii) cognitive function in healthy subjects fol-
lowing administration of pureΔ9-THC and CBD [52••, 53••];
(iii) cognitive function in healthy subjects following adminis-
tration of standardized cannabis extracts with defined Δ9-
THC:CBD ratios [54, 55]; (iv) cognitive function in human
subjects prescribed with medical marijuana (MMJ) containing
a low/balanced Δ9-THC:CBD ratio [56, 57].
Similarly, a review carried out in 2014 identified 24 studies
which used fMRI paradigms to explore the acute effects of
Δ9-THC or CBD on human brain function [49].Most of these
studies have investigated how these cannabinoids modulate
brain activity in the resting state or during cognitive process-
ing. However, a limited number of studies have specifically
compared the effects of pureΔ9-THC and CBD on the neural
substrates of human cognition [58••, 59, 60, 61••].
Finally, only one study has investigated the effect of anoth-
er cannabinoid, delta-9-tetrahydrocannabivarin (Δ9-THCV),
by comparing its effects on cognition with that of pure Δ9-
THC in healthy subjects [62] (Tables 1 and 2).
In contrast to studies on the effects of cannabis orΔ9-THC
on cognition, there has been very limited examination on the
effect of CBD alone on human cognition, with only two stud-
ies assessing the effect of CBD on cognitive function in
healthy subjects [58••] and in schizophrenia patients [63], re-
spectively. One of those exposed healthy participants to Δ9-
Table 1 Studies included in the review
Study Type of study Study sample Cannabinoids
investigated
Cognitive domain investigated
Wade et al. 2003
[57]
Randomized, double-blind,
cross-over, behavioral study
Patients with
neurological
disorders
Δ9-THC,
Δ9-THC +
CBD, CBD
Attention
Roser et al. 2008
[54]
Double-blind, cross-over, EEG
study
Healthy participants Δ9-THC,
Δ9-THC + CBD
Attention, processing speed
Morgan et al. 2010
[51]
Naturalistic, behavioral study Cannabis users Δ9-THC + CBD Verbal memory, episodic memory, executive function
Bhattacharyya
et al. 2010
[58••]
Randomized, double-blind,
cross-over fMRI study
Healthy participants Δ9-THC, CBD Verbal memory, emotional processing, executive
function, visual and auditory processing
Schoedel et al.
2011 [55]
Randomized, double-blind,
cross-over, behavioral study
Recreational cannabis
users
Δ9-THC,
Δ9-THC + CBD
Attention, processing speed, working memory
Winton-Brown
et al. 2011 [59]
Pseudo-randomized, double-blind,
cross-over, fMRI study
Healthy participants Δ9-THC, CBD Visual and auditory processing
Bhattacharyya
et al. 2012 [60]
Randomized, double-blind,
cross-over, fMRI study
Healthy participants Δ9-THC, CBD Attentional salience processing
Morgan et al. 2012
[50]
Naturalistic, behavioral study Cannabis users Δ9-THC + CBD Verbal memory, episodic memory, recognition
memory
Englund et al. 2013
[52••]
Randomized, double-blind,
behavioral study
Healthy participants Δ9-THC,
Δ9-THC + CBD
Verbal memory, working memory, executive function
Bhattacharyya
et al. 2015
[61••]
Randomized, double-blind,
cross-over, fMRI study
Healthy participants Δ9-THC, CBD Attentional salience processing
Hindocha et al.
2015 [53••]
Randomized, double-blind,
cross-over, behavioral study
Cannabis users Δ9-THC,
Δ9-THC +
CBD, CBD
Emotional processing
Gruber et al. 2016
[56]
Longitudinal, behavioral study Patients certified for
medical cannabis
Δ9-THC + CBD Executive function, processing speed
Englund et al. 2016
[62]
Double-blind, cross-over,
behavioral study
Healthy participants Δ9-THC,
Δ9-THC +
Δ9-THCV
Verbal memory, working memory
EEG electroencephalography, fMRI functional magnetic resonance imaging,Δ9-THC delta-9-tetrahydrocannabinol,CBD cannabidiol,Δ9-THCV delta-
9-tetrahydrocannabivarin, + investigated in combination
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THC, CBD, or placebo on separate occasions and is therefore
included in this review [58••]. The other study represents the
only published clinical trial to investigate the therapeutic po-
tential of CBD to treat cognitive impairment in a neuropsy-
chiatric condition. Unfortunately, it failed to show a signifi-
cant cognitive improvement in schizophrenia patients treated
with CBD [63].
Cognitive Function in Cannabis Users Using Products
with a High or LowΔ9-THC:CBD Ratio
The relative ratio ofΔ9-THC and CBD varies greatly in can-
nabis available on the street. For instance, in the UK, more
recent varieties of cannabis, such as “skunk,” have been
shown to contain more Δ9-THC and virtually no CBD com-
pared to the traditional “hash” variety [64]. A shift towards use
of high-potency cannabis with higher levels of Δ9-THC and
lower levels of CBD has been reported also in the USA [65]
and Australia [66]. In 2012, a meta-analysis of the studies
published over the previous three decades indicated that there
has been a consistent increase in cannabis potency worldwide
[67]. Recent research has indicated that the use of skunk-like
high-potency cannabis might have a more detrimental effect
on mental health than the use of the traditional low-potency
cannabis [5, 42], suggesting that the harmful effect of cannabis
might be driven by the high Δ9-THC/low CBD contained in
the used strain. However, despite being consistent so far, ev-
idence is too limited to draw definitive conclusions.
In a naturalistic study [51], Morgan and colleagues inves-
tigated cognitive processing among cannabis users as a func-
tion of the CBD content in the cannabis strain used by the
study participants. Results indicate that, upon acute intoxica-
tion, participants using low-CBD cannabis (<0.14%; n = 22)
performed worse than those using high-CBD cannabis
(>0.75%; n = 22) on a verbal memory task, despite there being
no difference in the concentration of Δ9-THC present in the
cannabis used during the experiment or in the baseline (before
acute intoxication) verbal memory performance between the
low- and high-CBD cannabis-using groups. Moreover, this
effect was still significant when controlling for the confound-
ing effect of alcohol use and intelligence. Together, these re-
sults suggest that CBD may attenuate the acute memory-
impairing effects of Δ9-THC.
In a second experiment, Morgan and colleagues assessed
cognitive functioning in chronic cannabis users when they
were not intoxicated as a function of the Δ9-THC:CBD ratio
in the strain of cannabis they used [50]. Results revealed a
better recognition memory in subjects using high-CBD can-
nabis compared to that in subjects using low-CBD cannabis.
Also, this association was independent of the frequency of use
(recreational use, n = 54; daily use, n = 66). Further analysis
also suggested an association between daily use of high Δ9-
THC cannabis and disruption of verbal and episodic memory.
Altogether, evidence from these studies suggests a higher risk
of memory disruption associated with consuming cannabis
strains with high Δ9-THC and low CBD content.
Cognitive Function in Healthy Subjects Following
Administration of PureΔ9-THC and CBD
A number of studies have investigated the effects of the major
cannabinoids such asΔ9-THC and CBD administered as pure
pharmacological grade substance to avoid the confounding
effects of different CBD and Δ9-THC concentrations and
other cannabinoids present in the cannabis extract. This re-
search design, which has been successfully used in preclinical
models, represents a promising paradigm in understanding the
neurobiological mechanisms underlying the effects of canna-
binoids on cognition [40].
Hindocha and colleagues investigated the main effects and
interaction of Δ9-THC and CBD on facial emotion recogni-
tion [53••]. Cannabis-using participants (n = 48) receivedΔ9-
THC, CBD, or their combination (Δ9-THC + CBD) over
separate sessions. Results indicate a detrimental effect of ad-
ministration ofΔ9-THC alone on emotional processing accu-
racy, which was no longer present when participants received
the Δ9-THC + CBD combination. Furthermore, administra-
tion of CBD alone was associated with higher emotional pro-
cessing accuracy compared to placebo. This study also re-
vealed that the effects of Δ9-THC and CBD on emotional
processing were not affected by the participants’ frequency
of cannabis use or schizotypal traits.
Using a slightly different approach, another study investi-
gated the putative protective effect of CBD against Δ9-THC-
induced impairments in cognitive processing [52••]. Healthy
participants were randomized to receive CBD or placebo be-
fore being intravenously administered with Δ9-THC.
Compared to the CBD pretreatment group (n = 22), the pla-
cebo pretreatment group (n = 26) showed a poorer verbal
memory performance following Δ9-THC administration.
Moreover, while Δ9-THC affected working memory perfor-
mance in participants pretreated with placebo, pretreatment
with CBD was able to partially prevent the detrimental effects
of Δ9-THC on this cognitive domain.
Cognitive Function in Healthy Subjects Following
Administration of Standardized Cannabis Extracts
with DefinedΔ9-THC:CBD Ratios
A few studies have investigated the effect of standardized
cannabis extracts containing precise combinations of Δ9-
THC and CBD. This approach complements studies investi-
gating the effects of pure pharmacological grade cannabinoids
by shedding new light on the potential cognitive mechanisms
that may underpin the harmful effects of specific types of
recreational cannabis [5, 42].
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Roser and colleagues investigated whether the acute effect
of standardized cannabis extracts on selective attention varies
as a function ofΔ9-THC being administered alone or in com-
bination with CBD [54]. Results indicate that cognitive per-
formance among healthy participants (n = 20) did not differ
significantly when administered with Δ9-THC alone or in
combination with CBD. However, compared to placebo, both
Δ9-THC alone and combinedΔ9-THC and CBD administra-
tion affected the attention-related electrophysiological re-
sponse. Another study assessed attention and working mem-
ory, exposing recreational cannabis users to increasing dos-
ages of Δ9-THC alone or to cannabis extracts containing in-
creasing balanced dosages of both Δ9-THC and CBD [55].
Results suggest that higher doses ofΔ9-THC were associated
with longer latency for short-term memory. Interestingly, this
effect on working memory was no longer present when par-
ticipants received any of the cannabis extracts containing both
Δ9-THC and CBD.
Cognitive Function in Individuals Treated with Medical
Marijuana
So far, only two studies have investigated the effect of MMJ
on cognition. Wade and colleagues tested for the effect ofΔ9-
THC, CBD, and a MMJ product containing a 1:1 Δ9-
THC:CBD ratio in patients with different neurological disor-
ders, mainly multiple sclerosis (n = 24) [57]. Administration
of Δ9-THC alone affected cognition in patients, as assessed
with a Short Orientation Memory Concentration test. Despite
no main effect of CBD on its own, when administered in
combination withΔ9-THC in the MMJ product, it prevented
the Δ9-THC-induced detrimental effect on cognition. More
recently, a pilot study has assessed the potential effect of a 3-
month treatment with MMJ on executive function [56].
Despite the modest sample size (n = 11), patients certified
for MMJ use experienced some improvement on measures
of executive function, mostly reflecting an increased process-
ing speed with preserved task accuracy.
Neural Substrates of Human Cognition Modulated
by Administration of PureΔ9-THC and CBD
Over the years, imaging studies investigating how cannabi-
noids modulate human brain function have employed progres-
sively more sophisticated designs. Recent studies have
allowed investigation of the effect of acute cannabinoid ad-
ministration on neural networks underlying specific cognitive
domains and their relationship to any concomitant effect on
cognitive task performance and neuropsychiatric symptom-
atology induced by the cannabinoids. This body of research
has complemented the behavioral evidence, testing specific
hypotheses for a role of the endocannabinoid system in vari-
ous cognitive processes.
Bhattacharyya and colleagues directly contrasted for the
first time the effects of Δ9-THC and CBD administration on
brain function and related behavior (n = 15) in healthy indi-
viduals, reporting opposite effects relative to placebo across
different cognitive domains [58••]. More specifically, during
the retrieval condition of a verbal memory task, CBD acutely
increased activation of the striatum and prefrontal cortex rel-
ative to the placebo condition. Conversely, Δ9-THC reduced
activity in these regions and the reduced striatal activation
correlated with the severity of the psychotic symptoms in-
duced by it. BothΔ9-THC and CBDmodulated the activation
of the amygdala and related brain regions involved in fear
processing, which correlated with their opposing effects on
anxiety, with effects of Δ9-THC correlating with increase in
anxiety symptoms and fear-related autonomic arousal induced
by it and effects of CBD correlating with a reduction in anx-
iety and attenuation of fear-related autonomic arousal under its
influence. During a response inhibition task, activation in the
parahippocampal gyrus bilaterally and in the left insula and
caudate was attenuated following Δ9-THC administration,
but enhanced under CBD. Finally, Δ9-THC and CBD in-
duced opposite effects while processing a response inhibition
task and auditory and visual stimuli.
In another study from the same sample, the authors report-
ed opposite effects ofΔ9-THC and CBD administration rela-
tive to that of placebo on several brain areas during attentional
salience processing [60]. More specifically, Δ9-THC acutely
reduced striatal activation which correlated with the severity
of the Δ9-THC-induced psychotic symptoms as well as the
Δ9-THC-induced behavioral response latency. A recent in-
vestigation in the same sample compared the effects of Δ9-
THC and CBD administration on functional connectivity dur-
ing the salience processing task [61••]. In line with previous
reports, the two cannabinoids had opposite effects on func-
tional connectivity between the dorsal striatum, the prefrontal
cortex, and the hippocampus. Specifically, mediotemporal-
prefrontal connectivity was enhanced under theΔ9-THC con-
dition but reduced following CBD administration. Instead,
fronto-striatal connectivity was enhanced byCBDbut reduced
underΔ9-THC. The effect ofΔ9-THC on fronto-striatal con-
nectivity also correlated with response latency while
performing the task.
Another study has directly compared the effects of Δ9-
THC and CBD administration on the processing of auditory
and visual stimuli [59]. Compared to CBD, while processing
auditory stimuli,Δ9-THC administration was associated with
reduced activity in the right superior and middle temporal
gyri. During the visual processing condition, Δ9-THC in-
creased activity in the primary visual cortex (left lingual and
middle occipital gyri) but attenuated it in occipital regions
bilaterally compared to CBD. Δ9-THC and CBD also had
opposite effects on cerebellar activity during visual
processing.
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Cognitive Function in Healthy Subjects Following
Administration of PureΔ9-THC andΔ9-THCV
To date, human studies have typically focused on Δ9-THC
and CBD, and their effects on brain function have been exten-
sively studied and well understood [41]. Only one recent study
has investigated the effect of another cannabinoid,Δ9-THCV,
a cannabinoid receptor 1 (CB1) neutral antagonist, on cogni-
tion in humans [62]. Englund and colleagues assessed the
acute effects of intravenous Δ9-THC administration on cog-
nition in healthy subjects (n = 10) following pretreatment with
Δ9-THCV or placebo for 5 days. Upon acute Δ9-THC ad-
ministration, participants pretreated with placebo experienced
an impairment in delayed verbal memory recall, which was no
longer present when participants were investigated following
pretreatment withΔ9-THCV. However, compared to the pla-
cebo pretreatment condition,Δ9-THC administration follow-
ingΔ9-THCV pretreatment was associated with significantly
increased memory intrusions.
Discussion
A Promising Approach to Understanding the Effects
of Cannabinoids on Cognition
Several potential confounders limit any inference being drawn
from studies investigating the association between chronic or
occasional cannabis exposure and cognitive processing alter-
ations. These include (i) considerable variation in the ratio of
different cannabinoids, in particular Δ9-THC:CBD ratio, in
cannabis used recreationally; (ii) interindividual variation in
frequency, quantity, and duration of cannabis use; (iii) modal-
ity of cannabis use, frequently consumed in combination with
tobacco and/or other substances; and (iv) neuroadaptive
changes that occur in relation to tolerance, withdrawal and/
or sensitization, and substance abuse/dependence in general.
In an attempt to control for these factors, several studies have
investigated the effect of each of these cannabinoids separate-
ly and contrasted them directly to determine whether the com-
position of cannabis matters in terms of its effects on human
cognition. These pharmacological challenge studies, which
we have reviewed here, offer the unique possibility of
perturbing the endocannabinoid system under controlled ex-
perimental conditions and investigating their effect on various
cognitive processes as well as acutely model cannabis-related
neuropsychiatric manifestations. This line of research also al-
lows us to systematically investigate under controlled experi-
mental conditions the therapeutic potential or indeed the
harmful effects of different cannabinoids that are increasingly
being considered as treatment for various neurodegenerative
and neuropsychiatric disorders. This research approach, espe-
cially when combined with neuroimaging techniques, can
provide insight into the neurobiological mechanisms underly-
ing the effects of cannabis on human cognition [11].
Cannabis Composition and Altered Cognitive Processing:
What and Where is the Evidence
Most of the available evidence so far relates to pharmacolog-
ical challenge studies involving two cannabinoids, Δ9-THC
and CBD, the most known and investigated cannabinoids at a
neurobiological level and in preclinical models [40]. Using
different research strategies, these two cannabinoids have
been administered as a crude extract (pure form), or in differ-
ent concentrations within recreational cannabis, standardized
cannabis extracts, or medicinal cannabis preparations.
Effect of Δ9-THC on Human Cognition and Related Neural
Activity
Compared to studies assessing the long-lasting effects of can-
nabis use on cognition [16, 18, 46, 68–70], there is much
better agreement across systematic experimental studies that
Δ9-THC administration acutely impairs several cognitive do-
mains, including emotional processing [53••], and verbal
[52••, 62] and working memory performance [52••].
Moreover, imaging studies have extended this evidence, indi-
cating acute Δ9-THC-induced changes in the neural activity of
brain areas underlying verbal memory, emotional and atten-
tive processing, and processing of visual and auditory stimuli
[58••, 59, 60, 61••]. Intriguingly, under the acute effect of Δ9-
THC, changes in these neural networks were associated with
the acute manifestation of psychotic symptoms [58••, 59, 60],
anxiety [58••], and impaired cognition at a behavioral level
[61••].
Effect of CBD on Human Cognition and Related Neural
Activity
Over the last few years, studies have also investigated the
effect of acute CBD administration on cognition, in quest of
a potential therapeutic effect of this cannabinoid [58••]. This
has followed evidence that CBDmay be an antagonist/inverse
agonist at cannabinoid receptor type 1 (CB1), in opposition to
Δ9-THC partial agonist effect [71], and additional evidence
for a potential anxiolytic effect of CBD, based on preclinical
[72–76] and clinical [77, 78] studies. Limited evidence so far
suggests that CBD administration might improve emotional
processing accuracy in cannabis users [53••]. Evidence from
imaging studies suggests that CBD attenuates amygdala activ-
ity while processing fearful stimuli, whichwas associatedwith
an attenuation of anxiety and the normal autonomic arousal
associated with fear processing [58••], consistent with inde-
pendent evidence of its anxiolytic potential [79]. On the con-
trary, CBD administration did not improve cognitive
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functioning in individuals suffering from neurological disor-
ders [57]. However, most of this evidence is based on single
studies, which need independent replication.
Comparison of the Effect of Δ9-THC and CBD on Human
Cognition and Related Neural Activity
Studies have investigated the effects of both Δ9-THC and
CBD, in their pure forms or in different combinations, in order
to test whether CBD may protect from or reverse the adverse
effects of Δ9-THC on cognition. Evidence from the studies
reviewed here seems to suggest the following: (i) Acute
cannabis-induced detrimental effects on verbal memory may
be greater when exposed to low-CBD cannabis [51]; (ii)
Chronic cannabis use may be associated with poorer verbal
and episodic memory when exposed to low CBD/high Δ9-
THC cannabis [50]; (iii) AcuteΔ9-THC-induced detrimental
effects on emotional processing and working memory are ab-
sent if Δ9-THC is administered in combination with CBD
[53••, 55]; (iv) Acute effects of Δ9-THC on attention may
not be distinguishable from acute effects of Δ9-THC admin-
istered in combination with CBD [54]; (v) Pretreatment with
CBDmay prevent the acuteΔ9-THC-induced impairments in
verbal and workingmemory processing [52••]; (vi) AcuteΔ9-
THC-induced impairments in cognition in patients with neu-
rological disorders may be absent ifΔ9-THC is administered
in combination with CBD in medicinal cannabis preparation
[57]; (vii) Medicinal cannabis, containing both Δ9-THC and
CBD, may have a beneficial effect on certain cognitive pro-
cesses in patients certified for its use [56]; (viii)Δ9-THC and
CBD have opposite effects on neural activity in brain areas
related to several cognitive processes [58••, 59, 60, 61••]; (ix)
Pretreatment with Δ9-THCV may prevent some of the acute
Δ9-THC-induced detrimental effects on verbal memory.
However, it is worth highlighting the need for independent
replication of evidence summarized here before they may be
generalized and useful for application in clinical settings.
Limitations and Future Perspectives
Studies included in this review need to be considered in light
of some limitations. On the basis of current evidence, it is
perhaps premature to conclude that any protective cognitive
effects in naturalistic studies are wholly attributable to CBD,
considering the numerous other chemicals present in cannabis
[50, 51]. It is unclear from existing research whether there is a
specific ratio of Δ9-THC and CBD at which the beneficial
effects of CBD outweigh any harmful effects of Δ9-THC on
cognition, such that this ratio may serve as a threshold for
consideration in the formulation of medicinal cannabis prep-
arations [56]. Whether Δ9-THCV has any beneficial effect is
unclear at this stage due to its mixed effects on memory and
also because current evidence comes from a single human
study with a modest sample size [62]. Research in humans,
especially on the effect of CBD and other cannabinoids, is still
in its infancy. So far, the only published study on the acute
effect of CBD in schizophrenia has not shown any significant
cognitive improvement [63]. Promising results of beneficial
effects of CBD on cognition in the context of neuropsychiatric
diseases come from preclinical studies on Alzheimer’s disease
(AD), indicating improved recognition, social recognition,
and spatial memory in AD paradigms following acute and
chronic CBD treatment (reviewed in [80]). To our knowledge,
no studies have explored the effect of CBD on cognition in
other drug-induced states. Future investigations need to inves-
tigate the effect of different cannabinoids on human cognition
to better understand their therapeutic potential as well as rel-
evance for neuropsychiatric conditions where the
endocannabinoid system or cannabis exposure may play a role
[12, 41, 42, 81–84].
Conclusions
Available evidence suggests that acute Δ9-THC administra-
tion has an adverse effect on several cognitive domains. In
particular, memory components appear to be the cognitive
domains more consistently disrupted following acute Δ9-
THC administration, including verbal, episodic, and working
memory. Less strong evidence suggests a deleterious effect of
Δ9-THC on attention and emotional processing. Furthermore,
the detrimental effects of cannabis exposure on cognition ap-
pear to be driven byΔ9-THC, with preparations containing a
high Δ9-THC:CBD ratio causing greater impairments in
emotional processing andmemory function compared to prep-
arations with lowΔ9-THC:CBD ratio. Limited evidence also
suggests potential beneficial effects of CBD alone on emo-
tional processing and some protective effects of CBD against
Δ9-THC-induced impairments in emotional processing and
memory function. Moreover, Δ9-THC and CBD appear to
have antagonistic effects on neural networks underlying sev-
eral cognitive processes, some of which correlate with the
harmful (e.g., Δ9-THC-induced psychotic or anxiety symp-
toms) or beneficial (e.g., anxiolytic effect of CBD) effects of
these cannabinoids on behavior.
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